CNIPA.AI

Company patentsInnovative medicines and biopharmaceuticals

COMPANY PATENT INTELLIGENCE

AstraZeneca Patent Portfolio Analysis

Explore medicines, formulations and related technologies through publications attributed to selected AstraZeneca legal entities.

Partial name or date coverage · counts are lower boundsData as of 2026-11-17Data scope
Search jurisdictions
Worldwide
Applicant-name basis
Dataset-harmonized assignees (not verified current owners)
Source search matches
957
Published 2025-01-01 — 2025-12-31 · Source Google Patents
Applicant names included in these statistics
ASTRAZENECA AB · ASTRAZENECA UK LTD
Publication dates collected
Not recorded in this snapshot
Reviewed names not covered
ASTRAZENECA UK LIMITED
Compare with other companies
Collected patent publications

≥957docs

80 per month · peak 2025-03 (111)

Empty dashed outlines are uncollected periods, not zero. Dashed bars have partial name or date coverage.

01Key figures

Applications
928
By application number; publication and grant count once
Invention
391
42% of applications
Utility model
0
0% of applications
Patent families
310
By the source family ID
Green technology
—
The source has no CPC codes
Concentration
1.00HHI
Sum of squared field shares; higher is more concentrated

INSIGHT 01Fact

90%

90% of applications are in Pharmaceuticals

805 applications in this field, 768 of them in IPC A61K — the main axis of the portfolio.

Method: Field applications ÷ applications with IPC

02Technology landscape

898 applications with IPC codes are mapped to 35 fields using the WIPO IPC–Technology Concordance; area is the number of applications. Select a tile to see its IPC subclasses. An application can belong to several fields.

  • Electrical engineering
  • Instruments
  • Chemistry
  • Mechanical engineering
Explore reviewed themes, sample patents and evidence

03Rhythm

Publications per month in each field; brighter cells mean more. It shows which directions surge in particular months.

This chart covers collected documents published from 2025-01-01 to 2025-12-31. Examination and publication processes affect this timing; it does not directly measure R&D investment in the same period.

Cells count publications only within the collected names and dates. Missing periods are not shown; the company portfolio is incomplete.
Technology field25-0125-0225-0325-0425-0525-0625-0725-0825-0925-1025-1125-12
Pharmaceuticals647597836262656360585778
Organic fine chemistry252543243025232220281636
Biotechnology192228301515142621211221
Medical technology1495522325114
Analysis of biological materials514224223215
Handling134210000000
Chemical engineering200113110000
Measurement000001001121

Filing years of the collected applications

Documents in the current publication window are deduplicated by application number and grouped by filing year. These are not the company's complete annual filings; older applications may only be published or granted within this window.

  • 20071
  • 20084
  • 20121
  • 201412
  • 201518
  • 20164
  • 201723
  • 20187
  • 201932
  • 202061
  • 202144
  • 202259
  • 2023262
  • 2024214
  • 2025186Publication lag may still apply

Invention applications are generally published about 18 months after filing, or priority where claimed, and may be published earlier. Flags are estimated as of 2026-11-17. An unflagged year is still not necessarily complete; these counts cannot establish growth or contraction in R&D.

Multi-year evolution · With a longer collection window, this becomes a yearly view that marks the fastest-growing and shrinking fields.

04Strategy profile

Four reproducible structural ratios, with the other published companies on the same scale. Entity scopes and windows can differ, so read relative positions only — this is not a ranking.

Concentration

1.00
0.001.43

Position 4 of 26 published companies.

Method: Sum of squared field shares

Utility model share

0%
0%33%

Position 9 of 26 published companies.

Method: Utility model documents ÷ all documents

Green technology share

—

The source has no CPC codes, so this cannot be computed.

Method: Documents with CPC Y02 ÷ documents with CPC

Manufacturing and inspection share

2.8%
0%50%

Position 12 of 26 published companies.

Method: Applications in measurement, chemical engineering, handling and machine tools ÷ all applications

05Collaboration

Organisations that filed jointly with the collected entities; line weight represents joint applications. Name-based candidates and reviewed relationships are labeled separately. Co-applications alone do not prove ownership.

DAIICHI SANKYO CO LTD25Other co-applicant · relationship unverified
MITSUBISHI TANABE PHARMA CORP20Other co-applicant · relationship unverified
ARRAY BIOPHARMA INC5Other co-applicant · relationship unverified
LOGICBIO THERAPEUTICS INC5Other co-applicant · relationship unverified
TAKEDA PHARMACEUTICALS CO5Other co-applicant · relationship unverified
FUSION PHARMACEUTICALS INC4Other co-applicant · relationship unverified
TRANSGENE4Other co-applicant · relationship unverified
INSMED INC3Other co-applicant · relationship unverified
IONIS PHARMACEUTICALS INC3Other co-applicant · relationship unverified
KYOWA KIRIN CO LTD3Other co-applicant · relationship unverified

Possible affiliation is a review lead only. Co-applicants without a review record are not automatically group members or external partners, and their independent filings are not added to these statistics.

Review the entity list

06Entities and scope

Entity review and data coverage are separate facts. This list shows the current entity configuration, evidence and relationship dates, matched name by name against this snapshot.

Filters change only the entity list below, not the statistics. A complete group snapshot is not available to switch to on this page.

Showing 2 of 2 entities

AstraZeneca AB

SubsidiaryVerifiedAll configured names covered
Names collected in this snapshot
AstraZeneca AB
Recorded relationship dates
Not recorded — Not recorded

年报第194–195页分别列明 AstraZeneca AB 和 AstraZeneca UK Limited 为100%子公司。两法人独立保留,不自动并入 MedImmune、Alexion 或其他名称变体。

Review evidence

AstraZeneca UK Limited

SubsidiaryVerifiedSome names covered
Names collected in this snapshot
ASTRAZENECA UK LTD
Names outside this snapshot
AstraZeneca UK Limited
Recorded relationship dates
Not recorded — Not recorded

年报第194–195页分别列明 AstraZeneca AB 和 AstraZeneca UK Limited 为100%子公司。两法人独立保留,不自动并入 MedImmune、Alexion 或其他名称变体。

Review evidence

Relationship dates help interpret renaming, acquisitions and joint ventures. Missing dates do not establish an indefinite relationship or verify the current patent owner.

07Observations

Written by editors after reading the patent texts and company materials. Verified facts and inferences are labeled, each with evidence and limits.

Technology themes and evidence

Select a theme to filter reviewed patents and observations that cite them. Counts are editorial samples only; one patent may belong to several themes. They do not describe the full portfolio distribution.

Themes describe the technical directions in these samples. Links to adoption in specific products, commercialization or commercial value have not been established.

Showing 2 sample patents · 0 linked observations

Reading samples

Hand-picked documents that illustrate technology themes — not a ranking of core patents and not representative of the whole.

US20250019666A1

Methods of purifying adenovirus

The abstract describes an adenovirus purification workflow intended for scale-up. Claim 1 starts with a sample from a host-cell population at approximately 4×10⁶ cells/mL or higher and combines depth filtration followed by microfiltration, anion-exchange chromatography, then tangential-flow filtration including ultrafiltration and diafiltration. The reading concerns the input conditions and sequence of separation operations.

Bibliography and claim evidence
Applicants
Astrazeneca Uk Limited
Application date
2021-12-10
Publication date
2025-01-16
English summary of cited claim evidence
US20250019666A1, claim 1 (reading note, not a verbatim quotation)The abstract describes an adenovirus purification workflow intended for scale-up. Claim 1 starts with a sample from a host-cell population at approximately 4×10⁶ cells/mL or higher and combines depth filtration followed by microfiltration, anion-exchange chromatography, then tangential-flow filtration including ultrafiltration and diafiltration. The reading concerns the input conditions and sequence of separation operations.
Legal status
Legal status and current ownership are unverified; applicant names retain the original source attribution.

US20250057764A1

Compositions, methods and systems for aerosol drug delivery

The abstract and claim 1 describe a composition deliverable by a metered-dose inhaler, combining pharmaceutical-grade HFC-152a propellant, active-agent particles and phospholipid particles with perforated microstructures. The active agent is selected from listed drug classes. The reading concerns the propellant and particle combination without inferring adoption by all inhalers or any particular marketed product.

Bibliography and claim evidence
Applicants
Astrazeneca Ab
Application date
2022-12-16
Publication date
2025-02-20
English summary of cited claim evidence
US20250057764A1, claim 1 (reading note, not a verbatim quotation)The abstract and claim 1 describe a composition deliverable by a metered-dose inhaler, combining pharmaceutical-grade HFC-152a propellant, active-agent particles and phospholipid particles with perforated microstructures. The active agent is selected from listed drug classes. The reading concerns the propellant and particle combination without inferring adoption by all inhalers or any particular marketed product.
Legal status
Legal status and current ownership are unverified; applicant names retain the original source attribution.

08Publication jurisdictions

39 publication offices · 957 documents

Counts use the publication office of each collected document, retaining publications from the same family in different jurisdictions. This is not a map of complete families, granted or active rights; WO and EP denote international and European publication routes.

  1. USUnited States126
  2. EPEuropean Patent Office publication122
  3. AUAustralia94
  4. WOPCT international publication77
  5. MXMexico74
  6. KRSouth Korea63
  7. TWTaiwan63
  8. ILIsrael61
Show 31 more jurisdictions
  1. ARArgentina29
  2. JPJapan20
  3. CLChile18
  4. COColombia16
  5. ESSpain16
  6. DKDenmark13
  7. MAMorocco13
  8. CRCosta Rica12
  9. DODominican Republic12
  10. FIFinland12
  11. PEPeru11
  12. PLPoland11
  13. PTPortugal11
  14. HUHungary10
  15. RSSerbia9
  16. LTLithuania8
  17. HRCroatia7
  18. SISlovenia6
  19. SMSan Marino6
  20. UYUruguay6
  21. MYMalaysia5
  22. ZASouth Africa5
  23. CNChina4
  24. NZNew Zealand4
  25. UAUkraine4
  26. FRFrance2
  27. GBUnited Kingdom2
  28. LULuxembourg2
  29. CACanada1
  30. JOJordan1
  31. MDMoldova1

09Documents

957 published documentsNewest first
  1. EP4635494A3

    Invention publication

    Amido heteroaromatic compounds

    ASTRAZENECA AB

    Organic fine chemistryPharmaceuticals

    2025-12-31
  2. EP4669668A1

    Invention publication

    Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)

    ASTRAZENECA AB

    BiotechnologyPharmaceuticals

    2025-12-31
  3. EP4669742A1

    Invention publication

    Methods for generating primary immune cells

    ASTRAZENECA AB

    BiotechnologyPharmaceuticals

    2025-12-31
  4. Inhibiteurs de l'arginase et leurs procédés d'utilisation

    ASTRAZENECA AB

    Organic fine chemistryPharmaceuticals

    2025-12-31
  5. Inhibiteurs de l'inflammasome nlrp3

    ASTRAZENECA AB / MITSUBISHI TANABE PHARMA CORP

    Organic fine chemistry

    2025-12-31
  6. Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques

    ASTRAZENECA AB

    Organic fine chemistryPharmaceuticals

    2025-12-31
  7. Nlrp3 inflammasome inhibitors

    ASTRAZENECA AB / MITSUBISHI TANABE PHARMA CORP

    Organic fine chemistry

    2025-12-31
  8. Amido heteroaromatic compounds useful in the treatment of liver diseases

    ASTRAZENECA AB

    Organic fine chemistryPharmaceuticals

    2025-12-31
  9. US12509702B2

    Invention grant

    Inducible modification of a cell genome

    ASTRAZENECA AB

    BiotechnologyOther special machines

    2025-12-30
  10. Nlrp3 inflammasome inhibitors

    ASTRAZENECA AB / MITSUBISHI TANABE PHARMA CORP

    Organic fine chemistry

    2025-12-29
  11. Amido heteroaromatic compounds useful in the treatment of liver diseases

    ASTRAZENECA AB

    Organic fine chemistryPharmaceuticals

    2025-12-29
  12. US2025388678A1

    Invention publication

    Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer

    ASTRAZENECA AB

    BiotechnologyPharmaceuticals

    2025-12-25
  13. EP4636400A3

    Invention publication

    Methods for increasing forced expiratory volume in asthmatics using benralizumab

    ASTRAZENECA AB

    Analysis of biological materialsBiotechnologyPharmaceuticals

    2025-12-24
  14. EP4665337A1

    Invention publication

    Prmt5 inhibitor for use in cancer therapy

    ASTRAZENECA AB

    Pharmaceuticals

    2025-12-24
  15. EP4665399A1

    Invention publication

    Combination therapies for treatment of cancer with therapeutic binding molecules

    ASTRAZENECA AB

    Pharmaceuticals

    2025-12-24
  16. JP2025186368A

    Invention publication

    Fused pyrimidine compounds as kcc2 regulator

    ASTRAZENECA AB

    Organic fine chemistryPharmaceuticals

    2025-12-23
  17. US12502355B2

    Invention grant

    Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine

    ASTRAZENECA AB

    Pharmaceuticals

    2025-12-23
  18. US12502398B2

    Invention grant

    Combination therapy for treating cancer

    ASTRAZENECA AB

    BiotechnologyPharmaceuticals

    2025-12-23
  19. US12503445B2

    Invention grant

    Compounds and their use

    ASTRAZENECA AB / MITSUBISHI TANABE PHARMA CORP

    Organic fine chemistryPharmaceuticals

    2025-12-23
  20. Anticuerpos anti-pseudomonas biespecíficos con regiones fc modificadas y métodos de uso de estos

    ASTRAZENECA AB

    Biotechnology

    2025-12-19

Titles come from the source bibliography. Select a number to read the full document on this site.

Drafting a patent in this field?

Upload your invention disclosure and get an editable draft that follows CNIPA practice.

Start drafting

10Method and sources

Counting units

Publications are deduplicated by publication number; applications by application number, so a publication and its grant count once; families by the source family ID. Technology fields are derived automatically from IPC codes using the WIPO IPC–Technology Concordance (March 2026), without manual or AI labeling.

Publication or grant documents do not establish current rights. Check legal status and current owners with the relevant patent office.

Entity scope

These statistics use only the applicant names and publication dates collected for this snapshot. They do not represent the full company or group portfolio.

Search jurisdictions
Worldwide
Applicant-name basis
Dataset-harmonized assignees (not verified current owners)
Applicant names included in these statistics
ASTRAZENECA AB · ASTRAZENECA UK LTD
Reviewed names not covered
ASTRAZENECA UK LIMITED
Current entity configuration and review evidence

The reviewed entities and aliases below describe the current company configuration. Only names listed above are covered by this snapshot.

AstraZeneca AB

Configured aliases: ASTRAZENECA AB

Original review note: 年报第194–195页分别列明 AstraZeneca AB 和 AstraZeneca UK Limited 为100%子公司。两法人独立保留,不自动并入 MedImmune、Alexion 或其他名称变体。

Review evidence

AstraZeneca UK Limited

Configured aliases: ASTRAZENECA UK LTD

Original review note: 年报第194–195页分别列明 AstraZeneca AB 和 AstraZeneca UK Limited 为100%子公司。两法人独立保留,不自动并入 MedImmune、Alexion 或其他名称变体。

Review evidence

Data sources

  • Google Patents · PartialPublished 2025-01-01 to 2025-12-31 · retrieved 2026-11-17 · 957 included · 0 out of scopeSource and terms

Found a wrong attribution or number? Tell us